Rivaroxaban Efficacy and Safety in SELECT-D Community Cancer-Associated Venous Thromboembolism Patients

被引：0
|
作者：
Carlin, Stephanie [1 ]
Gross, Peter L. [2 ,3 ]
机构：
[1] Hamilton Hlth Sci, Hamilton, ON, Canada
[2] McMaster Univ, Hamilton, ON, Canada
[3] McMaster Univ, C5-DBCVSRI, 237 Barton St East, Hamilton, ON L8L 2X2, Canada
来源：
JACC: CARDIOONCOLOGY | 2023年 / 5卷 / 02期
关键词：
cancer-associated thrombosis; real-word cohort;
D O I：
10.1016/j.jaccao.2022.12.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：201 / 202
页数：2
相关论文
共 50 条
  • [1] SELECT-D: Rivaroxaban versus Dalteparin for Patients with cancer-associated Thrombosis
    不详
    GEFASSCHIRURGIE, 2019, 24 (07): : 517 - 517
  • [2] Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)
    Marshall, Andrea
    Levine, Mark
    Hill, Catherine
    Hale, Danielle
    Thirlwall, Jenny
    Wilkie, Veronica
    French, Karen
    Kakkar, Ajay
    Lokare, Anand
    Maraveyas, Anthony
    Chapman, Oliver
    Arif, Azra
    Petrou, Stavros
    Maredza, Mandy
    Hobbs, Richard
    Dunn, Janet A.
    Young, Annie M.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (04) : 905 - 915
  • [3] Effectiveness and Safety of Rivaroxaban in Patients with Cancer-Associated Venous Thromboembolism
    Kohn, Christine G.
    Lyman, Gary H.
    Beyer-Westendorf, Jan
    Spyropoulos, Alex C.
    Bunz, Thomas J.
    Coleman, Craig I.
    BLOOD, 2017, 130
  • [4] Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomisation of the SELECT-D trial
    Marshall, A.
    Young, A. M.
    Levine, M.
    Hill, C.
    Hale, D.
    Thirlwall, J.
    Wilkie, V.
    French, K.
    Kakkar, A. K.
    Lokare, A.
    Maraveyas, A.
    Chapman, O.
    Arif, A.
    Petrou, S.
    Maredza, M.
    Hobbs, F. D. R.
    Dunn, J. A.
    THROMBOSIS RESEARCH, 2021, 200 : S36 - S36
  • [5] Efficacy and safety of rivaroxaban compared to enoxaparin in treatment of cancer-associated venous thromboembolism
    Simmons, Benjamin
    Wysokinski, Waldemar
    Saadiq, Rayya A.
    Bott-Kitslaar, Dalene
    Henkin, Stanislav
    Casanegra, Ana
    Lenz, Charles
    Daniels, Paul
    Bjarnason, Haraldur
    Vargas, Emily
    Hodge, David
    Holton, Sara J.
    Cerhan, James R.
    Loprinzi, Charles
    McBane, Robert
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (02) : 136 - 142
  • [6] Rivaroxaban for cancer-associated venous thromboembolism
    Liang, Bo
    Liang, Yi
    Zhao, Li-Zhi
    Zhao, Yu-Xiu
    Gu, Ning
    SCIENCE PROGRESS, 2021, 104 (02)
  • [7] Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer associated venous thromboembolism
    Oh, S. B.
    ANNALS OF ONCOLOGY, 2016, 27
  • [8] Retrospective evaluation of the efficacy and safety of rivaroxaban in patients with cancer-associated venous thromboembolism A single-center study
    Oh, Sang-Bo
    Seol, Young-Mi
    Kim, Hyo-Jeong
    Choi, Young-Jin
    MEDICINE, 2019, 98 (30) : e16514
  • [9] SELECT-D: Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism
    Young, Annie
    Dunn, Janet
    Chapman, Oliver
    Grumett, Joanne
    Marshall, Andrea
    Phillips, Jenny
    Lokare, Anand
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] Rivaroxaban in patients with cancer-associated thromboembolism
    Bauersachs, Rupert
    Voigtlaender, Minna
    Langer, Florian
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2022, 147 (23) : 1545 - 1551
12345